Standard BioTools Inc. Current Income Tax Expense (Benefit)
Standard BioTools Inc. (LAB) reported Current Income Tax Expense (Benefit) of $892.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-16
- Standard BioTools Inc. current income tax expense (benefit) for fiscal 2025 was $892.00K, a 165.48% increase from fiscal 2024.
- Standard BioTools Inc. current income tax expense (benefit) for fiscal 2024 was $336.00K, a 41.05% decline from fiscal 2023.
- Standard BioTools Inc. current income tax expense (benefit) for fiscal 2023 was $570.00K, a 15.85% increase from fiscal 2022.
- Standard BioTools Inc. current income tax expense (benefit) for fiscal 2022 was $492.00K.
| Period end | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $892.00K 10-K · filed 2026-03-16 | |
| 2024-12-31 | $336.00K 10-K · filed 2026-03-16 | |
| 2023-12-31 | $570.00K 10-K · filed 2026-03-16 | |
| 2022-12-31 | $492.00K 10-K · filed 2025-03-11 | |
| 2021-12-31 | -$104.00K 10-K · filed 2023-03-14 | |
| 2020-12-31 | $2.35M 10-K · filed 2022-03-08 | |
| 2019-12-31 | $599.00K 10-K · filed 2022-03-08 | |
| 2018-12-31 | $78.00K 10-K · filed 2021-02-25 | |
| 2017-12-31 | $518.00K 10-K · filed 2020-02-27 | |
| 2016-12-31 | -$272.00K 10-K · filed 2019-03-18 | |
| 2015-12-31 | $1.36M 10-K · filed 2018-03-08 | |
| 2014-12-31 | $274.00K 10-K · filed 2017-03-03 | |
| 2013-12-31 | $137.00K 10-K · filed 2016-02-29 | -$137.00K 10-K · filed 2014-03-12 |
| 2012-12-31 | $136.00K 10-K · filed 2015-02-26 | -$136.00K 10-K · filed 2013-03-12 |
| 2011-12-31 | -$166.00K 10-K · filed 2014-03-12 | |
| 2010-12-31 | -$83.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |